Company intelligence / Profile preview

ChromaVision Medical Systems

San Juan Capistrano, California, USA

Ownership: Private
Development stage: Other

Overview

ChromaVision's ACIS platform was FDA-cleared for diagnostic automation in cancer (notably HER2 for breast cancer), enabling higher accuracy in immunohistochemistry scoring, with ancillary applications in quantitative viral load and rare cell detection. The platform was widely adopted in US cancer diagnostics in the early 2000s, before the company was acquired.

Therapeutic areas: OncologyInfectious DiseasesRare Diseases
Modalities: Device
Industry: Pathology

Partnerships

Pathology Services Associates (PSA)Biopharmaceutical companies for companion diagnostics

Beyond the preview

Go deeper on ChromaVision Medical Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChromaVision Medical Systems.

Explore the full profile